MA29601B1 - Vaccin antipaludeen - Google Patents

Vaccin antipaludeen

Info

Publication number
MA29601B1
MA29601B1 MA30510A MA30510A MA29601B1 MA 29601 B1 MA29601 B1 MA 29601B1 MA 30510 A MA30510 A MA 30510A MA 30510 A MA30510 A MA 30510A MA 29601 B1 MA29601 B1 MA 29601B1
Authority
MA
Morocco
Prior art keywords
antipaludeen
vaccine
derivative
travelers
saponin
Prior art date
Application number
MA30510A
Other languages
English (en)
Inventor
Joseph D Cohen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34856445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29601B1 publication Critical patent/MA29601B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, entre autres, un procédé destiné à la prophylaxie de l'infection par le paludisme chez les voyageurs qui se rendent dans des régions endémiques, comprenant l'administration de quantités adéquates d'une formulation contenant un antigène de Plasmodium ou un fragment immunogénique ou un dérivé de celui-ci et un adjuvant, comprenant un dérivé de lipide A et une saponine dans une formulation liposomique.
MA30510A 2005-06-30 2007-12-26 Vaccin antipaludeen MA29601B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0513421.8A GB0513421D0 (en) 2005-06-30 2005-06-30 Vaccines

Publications (1)

Publication Number Publication Date
MA29601B1 true MA29601B1 (fr) 2008-07-01

Family

ID=34856445

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30510A MA29601B1 (fr) 2005-06-30 2007-12-26 Vaccin antipaludeen

Country Status (22)

Country Link
US (1) US9279006B2 (fr)
EP (1) EP1896060B1 (fr)
JP (1) JP5486802B2 (fr)
KR (2) KR20080030640A (fr)
CN (1) CN101208100A (fr)
AR (1) AR055069A1 (fr)
AU (1) AU2006265329B2 (fr)
BR (1) BRPI0613087A2 (fr)
CA (1) CA2613057C (fr)
EA (1) EA200702633A1 (fr)
ES (1) ES2529577T3 (fr)
GB (1) GB0513421D0 (fr)
IL (1) IL187769A0 (fr)
MA (1) MA29601B1 (fr)
MX (1) MX2007016240A (fr)
NO (1) NO20076200L (fr)
NZ (1) NZ564156A (fr)
PE (1) PE20070203A1 (fr)
TW (1) TW200800254A (fr)
UA (1) UA93508C2 (fr)
WO (1) WO2007003384A1 (fr)
ZA (1) ZA200710615B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657353A1 (fr) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
CA2679410C (fr) * 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Nouveau procede et nouvelles compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
CA2707245A1 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccin
BRPI0822098A2 (pt) * 2007-12-21 2015-06-30 Glaxosmithkline Biolog Sa Componente para uma vacina contra malária, vacina para malária, processo para a preparação do componente, uso do componente, e, método de tratar um paciente suscetível às infecções por plasmodium
EP2234638A1 (fr) 2007-12-24 2010-10-06 GlaxoSmithKline Biologicals SA Vaccins contre la malaria
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2011115684A2 (fr) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Compositions de vésicules lipidiques et procédés pour les utiliser
US9149432B2 (en) * 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
EP2566506B1 (fr) * 2010-05-07 2016-07-06 Virbac Composition vaccinale destinee a la prevention ou au traitement des leishmanioses
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
CN105431535A (zh) * 2013-06-03 2016-03-23 Vlp治疗有限责任公司 疟疾疫苗
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
BE1022373B1 (fr) * 2013-12-20 2016-03-25 Glaxosmithkline Biologicals S.A. Nouveaux vaccins antipaludeens
CA2938772C (fr) * 2014-02-05 2020-04-21 University Of Melbourne Procede et systeme pour la detection rapide de la malaria
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
WO2016184784A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides comprenant le domaine de liaison des protéines de plasmodium falciparum (cbp1 et cbp2) à cx3cl1 de chimiokine
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2018209265A1 (fr) * 2017-05-11 2018-11-15 Atreca, Inc. Anticorps antipaludéens qui se lient à la protéine circumsporozoïte
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
EP3947446A1 (fr) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau
EP4135847A4 (fr) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Vaccin contre un coronavirus
WO2021221127A1 (fr) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Immunothérapie à cytokine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0071705B1 (fr) 1981-05-21 1989-11-23 The Wellcome Foundation Limited Antigène protozoaire
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9002512D0 (en) 1990-02-05 1990-04-04 3I Res Expl Ltd Polypeptides and dna encoding same
GB9012580D0 (en) 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5198535A (en) 1991-01-10 1993-03-30 The United States Of America As Represented By The Secretary Of The Navy Protective malaria sporozoite surface protein immunogen and gene
CA2123612C (fr) * 1991-11-16 2002-06-25 Michel De Wilde Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
CA2138997C (fr) 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
WO1995012565A1 (fr) 1993-11-01 1995-05-11 E.I. Du Pont De Nemours And Company Procede de production de trichlorotrifluoroethanes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (fr) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998043690A1 (fr) 1997-03-29 1998-10-08 Ji Hoon Park Appareil pour injection en continu
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (fr) 1997-08-29 2014-01-28 Antigenics Inc. Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
WO2002077195A2 (fr) 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Proteine ama-1 de plasmodium falciparum et ses applications
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
EP2277533B1 (fr) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methodes de vaccination contre le paludisme
US7550275B2 (en) 2002-11-12 2009-06-23 The United States Of America As Represented By The Secretary Of The Navy Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
EP1754717A1 (fr) * 2005-08-19 2007-02-21 Université de Lausanne Peptides antigéniques et leurs utilisations

Also Published As

Publication number Publication date
AU2006265329A1 (en) 2007-01-11
KR20080030640A (ko) 2008-04-04
WO2007003384A1 (fr) 2007-01-11
ZA200710615B (en) 2009-02-25
TW200800254A (en) 2008-01-01
ES2529577T3 (es) 2015-02-23
AR055069A1 (es) 2007-08-01
UA93508C2 (en) 2011-02-25
BRPI0613087A2 (pt) 2012-10-09
NZ564156A (en) 2011-08-26
US20080317787A1 (en) 2008-12-25
EA200702633A1 (ru) 2008-06-30
EP1896060B1 (fr) 2014-12-03
CN101208100A (zh) 2008-06-25
CA2613057C (fr) 2016-02-02
GB0513421D0 (en) 2005-08-03
IL187769A0 (en) 2008-08-07
AU2006265329B2 (en) 2012-12-20
JP5486802B2 (ja) 2014-05-07
PE20070203A1 (es) 2007-03-28
NO20076200L (no) 2008-03-27
CA2613057A1 (fr) 2007-01-11
EP1896060A1 (fr) 2008-03-12
KR20130111648A (ko) 2013-10-10
JP2008544969A (ja) 2008-12-11
MX2007016240A (es) 2008-03-07
US9279006B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
ES2331952T3 (es) Fraccion de quil a con baja toxicidad y su uso.
EA200702633A1 (ru) Вакцина против малярии
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
MA30624B1 (fr) Vaccin anti-grippal
BRPI0010612B8 (pt) vacinas
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
EA201001189A1 (ru) Вакцинные композиции, содержащие сапониновый адъювант
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
EP0634937A1 (fr) Vaccins contenant des vesicules tensio actives non ioniques.
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
CY1111553T1 (el) Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση
DK1326636T3 (da) Vaccinesammensætning
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
MA29715B1 (fr) Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
MY129263A (en) Vaccine composition
BRPI0508813A (pt) vacinas de combinação com baixa dose de conjugado de hib
EP1206189A4 (fr) Formulations de vaccins antirotavirus
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
AR051023A1 (es) Vacunas que contienen antigeno de plasmodium
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
WO2005074460A3 (fr) Procedes pour ameliorer la reponse immunitaire dans une partie intradermique et composes utilises dans ces procedes
MA28035A1 (fr) Vaccin
MA32003B1 (fr) Vaccin